

Docket No. 60240/JPW/AJM/AJD

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ilya Trakht et al.

Serial No.: 09/664,958 Examiner: L. R. Helms

Filed: September 18, 2000 Group Art Unit: 1642

For: NOVEL TUMOR-ASSOCIATED MARKER

1185 Avenue of the Americas New York, New York 10036

November 12, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

\_ 21

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(c)(1) and §1.97(e)(1) to supplement the Information Disclosure Statements filed July 30, 2003 and September 19, 2003 in connection with the above-identified application.

According to 37 C.F.R. \$1.97(c), an Information Disclosure Statement shall be considered by the U.S. Patent and Trademark Office if filed before the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or any other Office Action which closes prosecution in the application, provided that the Information Disclosure Statement is accompanied by either (1) the statement specified in 37 C.F.R. §1.97(e)(1) or §1.97(e)(2), or (2) the fee set forth in 37 C.F.R. §1.17(p). Applicants annex hereto as Exhibit A a statement under 37 C.F.R. §1.97(e)(1), stating that each item of information contained in this Supplemental Information Disclosure Statement was first cited in International Search Report issued in connection with a foreign counterpart of the subject application, not more than three months prior to the filing of this Supplemental Information Disclosure Statement. A copy of this Search Report is attached

\* \*

3.3

Applicants: Ilya Trakht et al.

Serial No.: 09/664,958

Filed: September 18, 2000

Page 2

#### hereto as Exhibit B.

In accordance with their duty of disclosure under 37 C.F.R. \$1.56, applicants direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (Exhibit C), and attached hereto as Exhibits 1-5:

- PCT International Application No. PCT/GB90/02017, filed December 21, 1990, International Publication No. WO 91/09967, published July 11, 1991 (Exhibit 1);
- 2. Campbell AM (1986) Monoclonal Antibody Technology. Elsevier Publishing Co., New York, pp. 1-32 (Exhibit 2);
- 3. De Vries L, Lou X, Zhao G, Zheng B and Farquhar MG (1998)
  GIPC, a PDZ domain containing protein, interacts
  specifically with the C terminus of RGS-GAIP. Proc. Natl.
  Acad. Sci. USA 95: 12340-12345 (Exhibit 3);
- 4. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM et al. (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7: 13-21 (Exhibit 4); and
- 5. Rousset R, Fabre S, Desbois C, Bantignies F and Jalinot P (1998) The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins. Oncogene 16: 643-654 (Exhibit 5).

Applicants note that the fourth reference (Harlow and Lane, 1988) cited in the October 17, 2003 International Search Report (Exhibit B) has not been listed in the present Supplemental Information Disclosure Statement because this reference was previously made of record in the subject application, having been

Applicants: Ilya Trakht et al.

Serial No.: 09/664,958

Filed: September 18, 2000

Page 3

cited to the Examiner in the Supplemental Information Disclosure Statement filed July 30, 2003.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respect fully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commission for Patents P.O Box 1450, Alexandria VA 22313-1450

Alan J. Morrison

Reg. No. 37,399

John P. White

Registration No. 28,678

Alan J. Morrison

Registration No. 37,399

Attorneys for Applicant(s)
Cooper & Dunham, LLP

1185 Avenue of the

Americas

New York, New York 10036

(212) 278-0400



# Form PTO 1449

## **U.S. Department of Commerce** Patent and Trademark Office


Atty. Docket No. 60240/JPW/AJM/AJD	<b>Serial No.</b> 09/664,958
Applicant(s) Ilya Trakht et al.	

## INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date **Art Unit** 1642 September 18, 2000

Examiner		Document Number							Date	Name	Class	Subclass	Filing Date	
Initials		Document Number							Date	Name	Class	Subclass	If Appropriate	
					ļ									_
						L <u>.</u>					1000			
<del> </del>						ŀ	OF	CEIO	GN PATENT	DOCUMEN	TS		<b>T</b>	-1-44
			Do	cum	ent I	Num	ber		Date	Country	Class	Subclass	Translation Yes No	
-	1110						_	-	07/11/01	DOT	_		163	110
	WO	9	1	0	9	9	6	7	07/11/91	PCT	-			
•				-	-		-	,	• •				<u>.</u>	
					-						-			
											1.		<u></u>	
	ОТ		D D		  T   I   M/	IFN	TC	(Inc	luding Autho	r Title Dat	e Perti	nent Pages	Etc.)	
	<u> </u>							•	_			_		Co., N
	Campbell AM (1986) Monoclonal Antibody Technology. Elsevier Publi York, pp. 1-32;									υ	· .			
		Yo	ork,	pp.	1-3	<i>Z</i> ;								
		Yo De	ork, Vi	ries	L,	Lou	Χ,	Zha	o G, Zheng I	B and Farqui	har MG	(1998) GII	PC, a PD	Z dom
		Yo De co	ork, Vı ntai	ries ning	L, g pr	Lou otei	n, iı	ntera	cts specifical	3 and Farquily with the C	har MG termin	(1998) GII us of RGS-	PC, a PD GAIP. I	Z dom Proc. N
		You De co	ork, Vintai cad.	ries ning Sci LL	L, g pr . US	Lou otei SA 9 ardy	n, ii 95: 1 7 M	ntera 234 C, N	ncts specifical 0-12345; Maynard-Curri	ly with the C	termin H, Lou	us of RGS- uie DM et a	GAIP. I	Proc. No.
		You De co Ac Graspe	ork, Vintai cad. een	ries ning Sci LL ic h	L, g pr . US ., H	Lou otei SA 9 ardy an r	n, ii 95: 1 7 M non	ntera 234 C, I oclo	octs specificall 0-12345; Maynard-Curri nal antibodies	e CE, Tsuda from mice	termin H, Lou	us of RGS- uie DM et a	GAIP. I	Proc. N  Antig
		You De co Ac Grand Spellig	ork, valued. cad. ceen ecif	ries ning Sci LL ic h hair	L, g pr . US ., H numa	Lou otei SA 9 ardy an r ACs	n, ii 95: 1 7 M non . N	234 C, N oclo at. C	acts specificall 0-12345; Maynard-Curri nal antibodies Genet. 7: 13-21	e CE, Tsuda from mice; and	H, Lou	us of RGS- tie DM et a red with hu	GAIP. I al. (1994) iman Ig	Proc. No. 1
		You De co Ac Grand Spellig	ork, te Vintai cad. ceen ecifi tht couss	ries ning Sci LL ic h hair et R	L, g pr . US ., H num n Y R, F e Tax	Lou otei SA 9 ardy an r ACs abre	n, ii 95: 1 7 M non . N S,	234 C, Moclo at. C Des	octs specificall 0-12345; Maynard-Curri nal antibodies	e CE, Tsuda from mice; and gnies F and J	H, Louengineer	us of RGS- nie DM et a red with hu (1998) The	GAIP. I	Proc. No Antigo heavy a
		You De co Ac Grand Spellig	ork, vintai cad. een ecif tht c	ries ning Sci LL ic h hair et R	L, g pr . US ., H num n Y R, F e Tax	Lou otei SA 9 ardy an r ACs abre	n, ii 95: 1 7 M non . N S,	234 C, Moclo at. C Des	octs specificall 0-12345; Maynard-Curri nal antibodies Genet. 7: 13-21 bois C, Bantig	e CE, Tsuda from mice; and gnies F and J	H, Louengineer	us of RGS- nie DM et a red with hu (1998) The	GAIP. I	Antigo heavy a
		You De co Ac Grand Spellig	ork, te Vintai cad. ceen ecifi tht couss	ries ning Sci LL ic h hair et R	L, g pr . US ., H num n Y R, F e Tax	Lou otei SA 9 ardy an r ACs abre	n, ii 95: 1 7 M non . N S,	234 C, Moclo at. C Des	octs specificall 0-12345; Maynard-Curri nal antibodies Genet. 7: 13-21 bois C, Bantig	e CE, Tsuda from mice; and gnies F and J	H, Louengineer	us of RGS- nie DM et a red with hu (1998) The	GAIP. I	Antigo heavy a
		You De co Ac Grand Spellig	ork, te Vintai cad. ceen ecifi tht couss	ries ning Sci LL ic h hair et R	L, g pr . US ., H num n Y R, F e Tax	Lou otei SA 9 ardy an r ACs abre	n, ii 95: 1 7 M non . N S,	234 C, Moclo at. C Des	octs specificall 0-12345; Maynard-Curri nal antibodies Genet. 7: 13-21 bois C, Bantig	e CE, Tsuda from mice; and gnies F and J	H, Louengineer	us of RGS- nie DM et a red with hu (1998) The	GAIP. I	Antige heavy a
		You De co Ac Grand Spellig	ork, te Vintai cad. ceen ecifi tht couss	ries ning Sci LL ic h hair et R	L, g pr . US ., H num n Y R, F e Tax	Lou otei SA 9 ardy an r ACs abre	n, ii 95: 1 7 M non . N S,	234 C, Moclo at. C Des	octs specificall 0-12345; Maynard-Curri nal antibodies Genet. 7: 13-21 bois C, Bantig	e CE, Tsuda from mice; and gnies F and J	H, Louengineer	us of RGS- nie DM et a red with hu (1998) The	GAIP. I	Antige heavy a
		You De co Ac Grand Spellig	ork, te Vintai cad. ceen ecifi tht couss	ries ning Sci LL ic h hair et R	L, g pr . US ., H num n Y R, F e Tax	Lou otei SA 9 ardy an r ACs abre	n, ii 95: 1 7 M non . N S,	234 C, Moclo at. C Des	octs specificall 0-12345; Maynard-Curri nal antibodies Genet. 7: 13-21 bois C, Bantig	e CE, Tsuda from mice; and gnies F and J	H, Louengineer	us of RGS- nie DM et a red with hu (1998) The	GAIP. I	Antigo heavy a

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Examiner: L. R. Helms



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ilya Trakht et al.

Serial No.: 09/664,958

September 18, 2000 Group Art Unit: 1642

For: NOVEL TUMOR-ASSOCIATED MARKER

1185 Avenue of the Americas New York, New York 10036 November 12, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RECEIVED

NOV 2 5 2003

Sir:

Filed:

TECH CENTER 1600/2900

#### Statement Under 37 C.F.R. §1.97(e)(1)

Pursuant to 37 C.F.R. §1.97(e)(1), applicants hereby state that each item of information contained in this Supplemental Information Disclosure Statement was first cited in International Search Report issued October 17, in connection with International PCT Application PCT/US01/29242, a foreign counterpart of the subject application, not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Respectfully submitted,

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400